Loading clinical trials...
Loading clinical trials...
A Phase 3, Randomized, Double-Blind, Double-Dummy Study to Compare the Efficacy and Safety of Lefamulin (BC 3781) Versus Moxifloxacin (With or Without Adjunctive Linezolid) in Adults With Community-Acquired Bacterial Pneumonia
Conditions
Interventions
lefamulin
Moxifloxacin
+1 more
Locations
99
United States
Site 1006
Hazard, Kentucky, United States
Site 1008
Shreveport, Louisiana, United States
Site 1005
Minneapolis, Minnesota, United States
Site 1001
Butte, Montana, United States
Site 1009
Akron, Ohio, United States
Site 1002
Dayton, Ohio, United States
Start Date
September 1, 2015
Primary Completion Date
April 1, 2017
Completion Date
May 1, 2017
Last Updated
October 23, 2019
NCT07425561
NCT07109310
NCT06710080
NCT06210282
NCT02922387
NCT02269644
Lead Sponsor
Nabriva Therapeutics AG
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions